reports
Preferred Bank (Los Angeles, CA): 2 directors
A director at Preferred Bank (Los Angeles, CA) sold 900 shares at 78.080USD and the significance rating of the trade was 38/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
CoreCard Corporation Reports First Quarter 2024 Results
CoreCard Corporation Reports First Quarter 2024 Results NORCROSS, Ga., May 02, 2024 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended March 31, 2024. "Overall revenue of $13.1 million in the first quarter was in-line with our expectations, reflecting continued year-over-year growth in processing and maintenance of 13%, which was offset by lower professional ser...
- FIMA Research
Fima Daily Insight 02 May 2024
Please find enclosed our daily market report.Market CommentCroatia AD Plastik boosts net profit in Q1 Podravka Q1 net profit surges 48% YoY Hrvatski Telekom’s Q1 net profit down 1.7% SPAN plans to pay EUR 0.30 share dividend (DIVY 0.7%) Croatia's retail sales volume up real 8.9% in March Slovenia Slovenia's annual inflation rate down 0.6 p.p. in April to 3% Romania Transport Trade Services shareholders approve distribution of RON 68.4 mil as dividends Bulgaria Speedy nea...
Context Therapeutics Announces FDA Clearance of IND Application for a ...
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6...
Parker Reports Fiscal 2024 Third Quarter Results
Parker Reports Fiscal 2024 Third Quarter Results Sales were a record at $5.07 billion; organic sales increased 1%Segment operating margin was 21.5%, or a record 24.7% adjusted, an increase of 150 basis pointsEPS were $5.56, or a record $6.51 adjusted, an increase of 10%Company increases outlook for segment operating margin and EPS2024 Investor Meeting scheduled for May 16 at 2 p.m. Eastern time CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the fiscal 2024 third quarter e...
Map Aktif Adiperkasa Tbk PT: 1 director
A director at Map Aktif Adiperkasa Tbk PT bought 3,700,000 shares at 800.000IDR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Capricorn Metals Ltd: 1 director
A director at Capricorn Metals Ltd sold 2,011,539 shares at 4.900AUD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Biogen Reports Progress on Corporate Responsibility Priorities
Biogen Reports Progress on Corporate Responsibility Priorities Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) today announced publication of its detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders. “As we reflect on the past year and set our sights on the path ahead, I am truly inspired by the progress we have made to advance Biogen’s enduring legacy of pioneering inno...
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacoki...
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today ann...
Laureate Education Reports Financial Results for the First Quarter of ...
Laureate Education Reports Financial Results for the First Quarter of 2024 Company Increases Full-Year 2024 Guidance MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the first quarter of 2024. First Quarter 2024 Highlights (compared to first quarter 2023): New enrollments increased 1%.Total enrollments increased 5%.On a reported basis, revenue increased 10% to $275.4 million. On an organic constant currency basis1, revenue increased 1%...
Theratechnologies présentera des données à long terme sur l’efficacité...
Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO Dévoilement de données à long terme des parties 1 et 2 de l’essai clinique de phase I portant sur le sudocétaxel zendusortide dans les tumeurs solidesLa partie 3 de la phase I de l’essai sur le cancer de l’ovaire avancé se poursuit MONTRÉAL, 02 mai 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entre...
Quipt Home Medical Announces Normal Course Issuer Bid
Quipt Home Medical Announces Normal Course Issuer Bid CINCINNATI, May 02, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today that the Toronto Stock Exchange (“TSX”) has accepted the Company’s notice of intention to implement a normal course issuer bid (the “NCIB”). Under the NCIB, the Company may purchase for cancellation up to 3,626,845 common shares of the Company (each, a “Common Share”) from time to time in accordance with applicable secu...
FuelCell Energy and Toyota Motor North America Celebrate Launch of Wor...
FuelCell Energy and Toyota Motor North America Celebrate Launch of World's First "Tri-gen" Production System at the Port of Long Beach FuelCell Energy’s Tri-gen technology produces three products: renewable electricity, renewable hydrogen, and usable waterMarks Toyota’s first port vehicle processing facility in the world to be powered by onsite-generated, 100 percent renewable electricityBoth light-duty and Class 8 heavy-duty fuel cell electric vehicles have been fueled using Tri-gen generated renewable hydrogen LONG BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FCEL) and Toy...
Stack Capital Group Inc. Reports Q1-24 Financial Results
Stack Capital Group Inc. Reports Q1-24 Financial Results TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX: STCK and STCK.WT) today announced its financial results for the quarter ended March 31, 2024. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary: As at March 31, 2024, Book Value per Share (BVpS) of the Company was $11.03, compared with $10.91 as at December 31, 2023.Stack Capital increased its exposure to Locus Robotics through a share-swap transaction issuing 273,501 Stack Ca...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corp...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court date scheduled for April 21, 2025 Strong financial position – expected cash runway extended throu...
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Busi...
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update - Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abstracts accepted ...
The 2024 Xos SV Stepvan Now Available for Incentives on the HVIP Vehic...
The 2024 Xos SV Stepvan Now Available for Incentives on the HVIP Vehicle Catalog LOS ANGELES, May 02, 2024 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS), an industry-leading commercial electric vehicle manufacturer, has received official approval from the California Air Resources Board (CARB) for the 2024 Xos SV Battery Electric Stepvan to be listed on the Clean Truck and Bus Voucher Incentive Program (HVIP) catalog. The HVIP incentive, starting at a base amount of $85,000, offers Xos a significant opportunity to provide their innovative 2024 Xos SV Battery-Electric Stepvan at a reduced upf...
Notice of Knight Therapeutics' First Quarter 2024 Results Conference C...
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financial results on Thursday, May 9, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, May 9, 2024 Time: 8:30 a.m. ET Telephone: Toll Free: 1-800-836-8184 or International 1-...
Avis de conférence téléphonique de Thérapeutique Knight sur ses résult...
Avis de conférence téléphonique de Thérapeutique Knight sur ses résultats du premier trimestre 2024 MONTRÉAL, 02 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (ex. EU) et chef de file, publiera ses résultats financiers du premier trimestre 2024, ce jeudi 9 mai 2024 avant l’ouverture du marché. À la suite de cette publication, Knight sera l’hôte d’une conférence téléphonique et d’une webémission. Knight invite cordialement toutes les parties intéressées à participer à cet appel. Date : Jeudi 9 mai 2024 He...
Context Therapeutics Announces $100 Million Private Placement
Context Therapeutics Announces $100 Million Private Placement Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.